Conexeu Sciences (NASDAQ:CNXU) Director Buys $499,998.00 in Stock

Conexeu Sciences Inc. (NASDAQ:CNXU) Director Lynn Sebastian Purcell bought 166,666 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was purchased at an average cost of $3.00 per share, with a total value of $499,998.00. Following the purchase, the director directly owned 3,118,514 shares in the company, valued at $9,355,542. The trade was a 5.65% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Conexeu Sciences Trading Up 8.5%

NASDAQ:CNXU traded up $0.26 on Monday, reaching $3.32. The stock had a trading volume of 365,524 shares, compared to its average volume of 192,955. The stock has a market cap of $93.66 million and a P/E ratio of -8.30. The stock’s fifty day simple moving average is $5.45. Conexeu Sciences Inc. has a 12-month low of $3.05 and a 12-month high of $18.79.

Conexeu Sciences (NASDAQ:CNXU) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). As a group, analysts anticipate that Conexeu Sciences Inc. will post -0.40 earnings per share for the current year.

Analysts Set New Price Targets

CNXU has been the subject of several recent analyst reports. Zacks Research raised shares of Conexeu Sciences to a “hold” rating in a research note on Monday, June 29th. Weiss Ratings started coverage on Conexeu Sciences in a report on Monday, August 17th. They set a “sell (e-)” rating on the stock. Finally, HC Wainwright assumed coverage on Conexeu Sciences in a research report on Monday, June 22nd. They issued a “buy” rating and a $20.00 price objective for the company. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Conexeu Sciences currently has a consensus rating of “Hold” and a consensus target price of $20.00.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.